10-Q: Kalaris Q2 2025: Merger Boosts Cash, Losses Mount

Kalaris Therapeutics reports increased losses and cash burn in Q2 2025, despite a significant cash infusion from its merger with AlloVir, as it advances its lead retinal disease candidate TH103.

Summary

• Kalaris Therapeutics, Inc. (formerly AlloVir, Inc.) completed its merger with Legacy Kalaris on March 18, 2025, with Legacy Kalaris as the accounting acquirer.
• The company's common stock began trading on The Nasdaq Global Market under the ticker symbol KLRS on March 19, 2025.
• Legacy Kalaris securityholders now own approximately 74.47% of the combined company, while pre-closing AlloVir securityholders own approximately 25.53%.
• The company is a clinical-stage biopharmaceutical firm focused on developing TH103, a novel anti-VEGF drug for retinal diseases, with preclinical data showing superior activity and duration compared to aflibercept.
• A Phase 1 clinical trial for TH103 in neovascular Age-related Macular Degeneration (nAMD) is currently enrolling patients, with initial data expected in Q4 2025.
• The company incurred a net loss of $11.35 million for the three months ended June 30, 2025, compared to $5.65 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $21.55 million, up from $9.06 million in the prior year period.
• Research and development expenses increased by $5.23 million to $8.44 million for the three months ended June 30, 2025, driven by Phase 1 trial initiation and manufacturing activities.
• General and administrative expenses rose by $2.84 million to $3.82 million for the three months ended June 30, 2025, due to increased professional services and public company costs.
• Net cash used in operating activities was $19.98 million for the six months ended June 30, 2025, compared to $8.49 million for the same period in 2024.
• Cash and cash equivalents stood at $88.43 million as of June 30, 2025, significantly up from $1.64 million at December 31, 2024, primarily due to $102.1 million cash acquired in the merger.
• The company expects its existing cash and cash equivalents to fund operations into the fourth quarter of 2026.
• Material weaknesses in internal control over financial reporting identified as of December 31, 2024, remain unremediated as of June 30, 2025.
• A securities class action lawsuit related to AlloVir's legacy operations was settled for $1.0 million and dismissed with prejudice on July 30, 2025.
• A derivative lawsuit against AlloVir's former officers/directors was voluntarily dismissed without prejudice on August 1, 2025.
• Two complaints related to the merger, alleging misrepresentation in the proxy statement, are ongoing.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant and increasing losses, high cash burn, and identified material weaknesses in internal controls. While the merger provided a cash infusion and preclinical data for TH103 is positive, the company remains in early clinical stages with substantial funding needs and high execution risk, outweighing the positive cash position from the merger.

Positives

• The merger with AlloVir provided a significant cash infusion of approximately $102.1 million, substantially increasing cash and cash equivalents to $88.43 million as of June 30, 2025.
• The company projects its current cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2026.
• Preclinical studies for the lead product candidate, TH103, showed more anti-VEGF activity and longer duration of activity compared to aflibercept, a current market leader.
• The Phase 1 clinical trial for TH103 in nAMD patients is actively enrolling, with initial clinical data anticipated in Q4 2025, marking progress in development.
• The company plans to expand TH103 development into other prevalent VEGF-mediated retinal diseases, including Diabetic Macular Edema (DME), diabetic retinopathy (DR), and Retinal Vein Occlusion (RVO).
• The securities class action lawsuit related to AlloVir's legacy operations was settled for $1.0 million and dismissed with prejudice, resolving a significant legal overhang.
• A derivative lawsuit against AlloVir's former officers and directors was voluntarily dismissed without prejudice, further reducing legacy legal exposure.

Negatives

• The company continues to incur significant operating losses, with a net loss of $11.35 million for Q2 2025 and $21.55 million for the six months ended June 30, 2025.
• Negative cash flows from operations persist, totaling $19.98 million for the six months ended June 30, 2025.
• The accumulated deficit has grown to $138.11 million as of June 30, 2025, indicating a history of unprofitability.
• Material weaknesses in internal control over financial reporting identified as of December 31, 2024, remain unremediated as of June 30, 2025, posing a risk of financial misstatements.
• The company has never generated revenue from product sales and may never achieve or maintain profitability.
• There is a heavy dependence on the success of a single lead product candidate, TH103, which is still in early clinical development.
• The company will need substantial additional funding beyond the current cash runway to continue product development and potential commercialization.

Risks

• Significant losses and negative cash flows are expected to continue, and profitability may never be achieved or maintained.
• Heavy dependence on the success of TH103, which requires significant clinical testing and may not receive marketing approval or be successfully commercialized.
• Substantial additional funding will be needed; inability to raise capital on acceptable terms could force delays, reductions, or elimination of product development programs.
• Identified material weaknesses in internal control over financial reporting remain unremediated, potentially leading to material misstatements.
• Early stage of development means significant delays or inability to commercialize TH103 or other candidates would materially harm the business.
• Even if approved, TH103 may fail to achieve sufficient market acceptance by physicians, patients, and third-party payors.
• Reliance on third parties (CROs) to conduct clinical trials carries risks of unsatisfactory performance or failure to meet deadlines.
• Inability to obtain and maintain sufficient intellectual property protection for technology and product candidates could allow competitors to commercialize similar products.
• The regulatory approval process is expensive, time-consuming, and uncertain, with no guarantee of timely approval or approval at all.
• The market price of common stock has been and is expected to continue to be volatile.
• Inability to successfully integrate the businesses of AlloVir and Legacy Kalaris and realize anticipated merger benefits.
• Increased costs and demands on management due to compliance with public company laws and regulations.
• Uncertainty whether an active, liquid, and orderly trading market will develop for common stock.
• Executive officers, directors, and principal stockholder (Samsara LP) have significant control or influence over stockholder matters.
• Samsara LP's majority ownership makes the company a 'controlled company' under Nasdaq rules, allowing exemptions from certain corporate governance requirements.
• Ability to use net operating loss carryforwards (NOLs) and research and development tax credit carryforwards may be subject to limitations (e.g., Section 382).
• Delays or difficulties in patient enrollment for clinical trials could delay or prevent marketing approvals.
• Identification of dose-limiting toxicities, serious adverse events, or undesirable side effects could lead to abandonment or limitation of product development.
• Post-marketing discovery of reduced effectiveness or new undesirable side effects could compromise product marketing.
• Expending limited resources on one product candidate may cause failure to capitalize on more profitable opportunities.
• Substantial competition in the biopharmaceutical industry from larger, more established companies.
• Exposure to clinical trial and product liability lawsuits.
• Complexity of manufacturing biologics may lead to production issues or interruptions.
• Reliance on single-source suppliers for certain manufacturing materials and components.
• Collaborations with third parties for development and commercialization may not be successful.
• Acquisitions or in-license transactions could disrupt business, cause dilution, or reduce financial resources.
• Inability to protect intellectual property rights globally, especially in countries with weaker IP laws.
• Changes in tax laws or their interpretation could adversely affect business and financial condition.
• Uncertainty surrounding U.S. trade policy, including tariffs, could impact costs and supply chains.
• Disruptions at the FDA and other government agencies (e.g., funding cuts, personnel losses) could hinder timely guidance and approvals.
• Recently enacted and future legislation may increase the difficulty and cost of commercialization and affect pricing.
• Stringent privacy and information security laws and regulations could lead to fines and penalties for non-compliance.
• Misconduct by employees, contractors, or third parties could lead to significant liability and reputational harm.

Future Outlook

The company expects to continue incurring substantial losses for the foreseeable future as it advances TH103 through clinical trials and pursues regulatory approval. It does not anticipate generating revenue from commercial product sales unless and until successful development and regulatory approval are achieved. The existing cash and cash equivalents are expected to fund operations into the fourth quarter of 2026, but substantial additional funding will be required thereafter. The company plans to expand TH103 development beyond nAMD into other prevalent VEGF-mediated retinal diseases such as DME, DR, and RVO. Initial clinical data from Part 1 of the Phase 1 clinical trial for TH103 in nAMD is expected in Q4 2025.

Management Comments

• We expect to continue to incur substantial losses for the foreseeable future, and our ability to achieve and sustain profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support the Company’s operations.
• We expect that the existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance date of these condensed consolidated financial statements.
• We will need to raise additional financing to continue its product’s development for the foreseeable future until it becomes profitable.
• We plan to monitor expenses and raise additional capital through a combination of equity and debt financings, strategic alliances, and licensing arrangements.
• Our management expects that our cash and cash equivalents as of June 30, 2025 will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2026. However, we have based these estimates on assumptions that may prove to be wrong, and our operating plans may change as a result of many factors currently unknown to us.
• We are actively recruiting additional accounting personnel with appropriate experience, certification, education and training.
• We are in the process of implementing additional measures and risk assessment procedures designed to improve our disclosure controls and procedures and internal control over financial reporting to address the underlying causes of these material weaknesses, including the implementation of appropriate segregation of duties, formalization of accounting policies and controls, and implementation of accounting systems to automate manual processes.
• We have engaged financial consultants to assist with the implementation of internal controls over financial reporting and are actively recruiting a chief financial officer.

Industry Context

The biopharmaceutical industry, particularly the retinal disease market, is characterized by intense competition and rapid technological advancements. Kalaris Therapeutics is entering a market with established anti-VEGF therapies from major pharmaceutical companies like Novartis, Regeneron, AbbVie, and Roche, as well as emerging biosimilars. The company's TH103 aims to differentiate itself with potentially longer-lasting and increased anti-VEGF activity. The broader macroeconomic trends, including inflation, interest rate fluctuations, and geopolitical tensions, are noted as potential factors increasing capital costs and limiting access to funding for the industry.

Comparison to Industry Standards

• TH103, Kalaris' lead candidate, showed more anti-VEGF activity and longer duration in head-to-head preclinical studies compared to aflibercept (Regeneron's Eylea), a current global market-leading anti-VEGF agent. This suggests a potential competitive advantage if these preclinical findings translate to clinical success.
• The market for anti-VEGF therapies for retinal diseases is well-established, with key competitors including Novartis (brolucizumab), Regeneron (aflibercept, aflibercept HD), AbbVie (collaborating on ABBV-RGX-314), and Roche (faricimab, ranibizumab, bevacizumab).
• Several biosimilars to ranibizumab (Byooviz, Cimerli) and aflibercept (Opuviz, Ahzantive, Yesafili, Pavblu) have received FDA approval, indicating increasing generic competition and potential pricing pressure in the market.
• Emerging biopharmaceutical companies like 4D Molecular Therapeutics, Adverum Biotechnologies, and RegenexBio are advancing anti-VEGF gene therapy candidates, representing a different modality of competition. Eyepoint Pharmaceuticals and Ocular Therapeutix are also developing sustained-release small molecule inhibitors, indicating diverse competitive approaches.
• Kalaris' current stage of development (Phase 1 for TH103) is significantly earlier than many competitors who have approved products or candidates in pivotal/Phase 3 trials, highlighting the long and uncertain path to market.
• The company's reliance on third-party CDMOs and CROs for manufacturing and clinical trials is a common industry practice for clinical-stage biotechs, but it introduces dependence and potential risks if these partners do not perform satisfactorily.

Management Changes

Corporate Governance

Legal Proceedings

• A securities class action lawsuit, Zerbato v. AlloVir, Inc. et al., filed on January 19, 2024, alleging false and misleading statements regarding AlloVir's Phase 3 studies of posoleucel, was settled for $1.0 million on April 14, 2025, and dismissed with prejudice on July 30, 2025.
• A derivative lawsuit, Lister v. Brainard et al., filed on October 21, 2024, against certain AlloVir officers and directors, alleging breach of fiduciary duties and other claims, was voluntarily dismissed without prejudice on August 1, 2025.
• Two individual actions, Keller v. AlloVir, Inc. et al. and Morgan v. AlloVir, Inc. et al., filed on February 19-20, 2025, by purported AlloVir stockholders, allege misrepresentation and/or omission of material information in the proxy statement/prospectus describing the merger. These complaints seek various remedies including enjoining the merger, requiring an amended proxy statement, rescinding the merger, or granting rescissory damages. The company denies these allegations.

Related Party Transactions

• Samsara BioCapital L.P. and its affiliates are the company's majority stockholder and a related party, having provided significant equity and debt financing since inception.
• Samsara provided in-kind research and development and general and administrative services since inception, and cash-based general and administrative services (accounting, HR, executive assistance) since April 2022 under a Business Services Agreement (BSA).
• The company recognized immaterial amounts for BSA services for the three months ended June 30, 2025, and $0.2 million for the six months ended June 30, 2025, as general and administrative expenses.
• Samsara stopped providing in-kind services in July 2024.
• A Royalty Agreement was entered into with Samsara in July 2024, where the company redeemed 10,080 common shares in exchange for a low single-digit percentage tiered royalty on net sales of products developed using UCSD-licensed technology.
• An initial royalty obligation liability of $32.1 million was recognized as a long-term liability under the Royalty Agreement, with the $32.0 million excess over the fair value of repurchased shares recorded as a research and development expense in July 2024.
• Royalty payments to Samsara were not probable and estimable as of June 30, 2025, so no interest expense was recognized for the royalty liability.
• The company issued convertible promissory notes to Samsara and other related parties, including the 2024 Note (up to $10.0 million), 2024 Bridge Notes (up to $25.0 million), and 2025 Bridge Notes ($3.75 million).
• The AlloVir Note ($3.75 million) issued to AlloVir in January 2025 was cancelled upon the merger closing.
• All outstanding convertible promissory notes (except the AlloVir Note) were converted into common stock or Series B-2 preferred stock (then common stock) in connection with the merger.

Stakeholder Impact

• **Shareholders:** Experience significant dilution from past and potential future capital raises. The 'controlled company' status due to Samsara LP's ownership may limit the influence of other shareholders on corporate governance. The stock price is expected to remain volatile due to early development stage, financial losses, and market conditions. Legal proceedings related to the merger could create uncertainty.
• **Employees:** The company is expanding its workforce, particularly in R&D, clinical, and administrative functions, which could offer growth opportunities. However, the ongoing recruitment for a CFO and remediation of internal control weaknesses may create some operational instability. The company sponsors a 401(k) plan.
• **Customers (future):** The success of TH103 could offer a new, potentially more effective treatment option for prevalent retinal diseases, addressing unmet medical needs. However, market acceptance and reimbursement will be critical for patient access.
• **Suppliers/Creditors:** The company's reliance on third-party CDMOs and CROs for manufacturing and clinical trials means these partners are critical to its operations. The need for substantial additional funding could impact the company's ability to meet future obligations if capital is not secured.
• **Regulatory Authorities:** The company is subject to stringent regulatory requirements for drug development, approval, and post-marketing. Compliance failures could lead to penalties and impact product availability. Changes in regulatory policies (e.g., FDA, EU) could affect development timelines and costs.

Next Steps

• Continue enrolling patients in the Phase 1 clinical trial of TH103 in nAMD.
• Report initial clinical data from Part 1 of the Phase 1 clinical trial in the fourth quarter of 2025.
• Expand the development of TH103 beyond nAMD into other prevalent VEGF-mediated retinal diseases (DME, DR, RVO).
• Recruit additional accounting personnel and a Chief Financial Officer.
• Implement additional measures and risk assessment procedures to remediate material weaknesses in internal control over financial reporting.
• Monitor expenses and raise additional capital through equity and debt financings, strategic alliances, and licensing arrangements.
• Continue to evaluate the impact of the One Big Beautiful Bill Act and other tax reform legislation on financial statements.

Key Dates

Recommendation

Kalaris Therapeutics is in a very early, high-risk stage of development, heavily reliant on a single product candidate, TH103. While the recent merger provided a substantial cash infusion, the company continues to incur significant losses and negative cash flows, with a projected cash runway only into Q4 2026, necessitating further capital raises. The preclinical data for TH103 is promising, but clinical success is highly uncertain, and initial Phase 1 data is not expected until Q4 2025. The identified material weaknesses in internal controls add a layer of operational risk. Given the substantial risks, including the early stage of development, significant cash burn, and the need for future financing, a 'buy' recommendation is premature. However, the cash position from the merger provides a temporary buffer, and the potential of TH103 in a large market (retinal diseases) warrants continued observation. Therefore, a 'hold' recommendation is appropriate for investors who are already exposed or considering a speculative position, acknowledging the high risk but also the potential for future upside if clinical milestones are met and financial stability improves.

Keywords

Biopharmaceutical, Retinal Disease, TH103, VEGF Inhibitor, Clinical Stage, Ophthalmology, nAMD, Diabetic Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, SEC Filing, 10-Q, Biotech, Drug Development, Clinical Trials